Loading...
•
Mar 31, 2023
Heron Therapeutics Q1 2023 Earnings Report
Reported net product sales growth and highlighted the appointment of a new CEO.
Key Takeaways
Heron Therapeutics reported a 26% increase in net product sales for Q1 2023, reaching $29.6 million, driven primarily by the oncology care franchise. The company is focused on enhancing the value of ZYNRELEF, addressing application issues, and reducing cash burn through improved operational efficiency.
Net product sales for Q1 2023 grew 26% to $29.6 million compared to Q1 2022.
Oncology care franchise net product sales increased 15% to $25.8 million compared to the same period in 2022.
ZYNRELEF net product sales were $3.5 million for the three months ended March 31, 2023.
APONVIE net product sales were $0.3 million for the three months ended March 31, 2023, following its launch in March.
Heron Therapeutics
Heron Therapeutics
Heron Therapeutics Revenue by Segment
Revenue by Segment
CINVANTI Revenue
CapyFin.comSUSTOL Revenue
CapyFin.comZYNRELEF Revenue
CapyFin.comAPONVIE Revenue
CapyFin.com Forward Guidance
The company is focused on reducing cash burn and streamlining the organization to achieve significant growth and improve patient outcomes.
Revenue & Expenses
Visualization of income flow from segment revenue to net income